VivoSeq
Other

Onabotulinumtoxina

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

OnabotulinumtoxinA is an early-stage landscape with 0 programs across 1 company. The most active players are AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed10 · 59%
Recruiting2 · 12%
Active, not recruiting1 · 6%
Withdrawn1 · 6%
Not yet recruiting1 · 6%
Unknown status1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

17 trials

Impact of OnabotulinumtoxinA (BOTOX®) on Stress
Recruiting·CCenter for Advanced Facial Plastic Surgery·Phase 1·NCT06778421·20 enrolled
Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA
Recruiting·—·Phase 4·NCT05519072·140 enrolled
A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants
Active, not recruiting·AbbVie logoAbbVie·Phase 3·NCT06794866·150 enrolled
Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
Not yet recruiting·WWomen and Infants Hospital of Rhode Island·Phase 4·NCT06953271·164 enrolled
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
Completed·AbbVie logoAbbVie·Phase 1·NCT06834789·132 enrolled
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
Completed·TThe Cleveland Clinic·Phase 4·NCT05719285·100 enrolled
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
Completed·AbbVie logoAbbVie·Phase 3·NCT05134649·292 enrolled
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
Completed·AbbVie logoAbbVie·Phase 3·NCT04994535·426 enrolled
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence
Completed·AbbVie logoAbbVie·Phase 3·NCT04949399·408 enrolled
Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides
Completed·LLupo Center for Aesthetic and General Dermatology·Phase 1·NCT05807412·10 enrolled
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Completed·AbbVie logoAbbVie·Phase 2·NCT03861936·150 enrolled
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Completed·AbbVie logoAbbVie·Phase 2·NCT05100199·328 enrolled
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Completed·AbbVie logoAbbVie·Phase 2·NCT05013424·92 enrolled
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
Completed·WWake Forest University Health Sciences·Phase 1·NCT05769478·21 enrolled
OnabotulinumtoxinA Bladder Injection Study
Terminated·CCorewell Health East·Phase 4·NCT03523091·6 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)